الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 135 |  |  |
| | | from | 135 | | |
Abstract
Skin psoriasis is a common chronic, inflammatory immune-mediated skin disease affecting about 2% of the general population. PsO has various morphologies, distributions, and courses of the disease. The most prevalent coexisting condition in PsO is inflammatory arthritis, termed PsA, which develops in up to 30% of patients with PsO. PsA is a chronic, progressive inflammatory joint disease that can lead to severe joint damage, disability, and loss of function. It is difficult to determine the definite prevalence of joint involvement in PsO, which some predict ranges from 7 to 40%, of which 25% are undiagnosed due to subclinical involvement and absence of inflammatory signs, causing permanent joint damage and disability.
Progressive radiographic joint damage and worse physical function result from diagnostic delay of even 6 months with a much lower treatment response. Early detection of MSK and joint involvement in PsO patients and early treatment is a must to improve the prognosis.
Computed tomography is considered the “gold standard” in evaluating bone lesions, offering excellent imaging of bone structures. It can detect bone changes in PsA as well as PsO patients in the form of erosions and new bone formation at entheseal sites.
Both PsO and PsA have been shown to have a negative impact on an individual’s perception of QoL. PsA patients have more functional disability and reduced QoL compared with PsO patients without arthritis.
For that reason, the aim of this study was to detect early periarticular bone changes in psoriatic patients with or without joint involvement and to detect any possible effect of such changes on QoL of the involved patients.